Tests an electromagnetic device for autoimmune conditions like lupus and multiple sclerosis
Tests low-frequency electromagnetic sessions against a sham device in people with autoimmune disease.
Plain-language title generated from the registry record
Registry title: Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)New York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Truway Health, Inc.
- Trial code
- NCT07221565
- Record updated
- 22 May 2026
- Original description
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis.Read full original descriptionShow less
ImmuneNet: Quantum-Synaptic Immunotherapy Mapping
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis.
Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells.
A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy.
The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Inclusion: Male or female participants aged 18-70 years; Clinical diagnosis of a systemic autoimmune disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, or multiple sclerosis) confirmed for at least 12 months; Stable disease-modifying therapy or corticosteroid regimen for at least 8 weeks prior to enrollment; Willingness to maintain current medication schedule for the duration of the study; Ability to provide written informed consent and comply with study procedures; Access to stable internet or smartphone connection for digital consent verification and symptom tracking.
Exclusion: Prior participation in any electromagnetic or quantum resonance study within the past 6 months; Use of biologic or investigational therapy initiated within the previous 3 months; Active infection, malignancy, or significant hepatic, renal, or cardiovascular disease; Known photosensitivity, seizure disorder, or history of uncontrolled epilepsy; Presence of an implanted medical or electronic device (e.g., pacemaker, defibrillator, deep brain stimulator); Pregnancy or lactation; Inability to attend at least 80% of treatment sessions or follow-up visits.